Heparin-induced thrombocytopenia in the pediatric population: a review of current literature
Review published in J Pediatr Pharmacol Ther (2012)
Abstract
Heparin-induced thrombocytopenia is a rare and serious reaction to unfractionated heparin and low-molecular-weight heparins in children. Quick recognition, discontinuation of heparin, and subsequent treatment with an alternative anticoagulant are essential steps to prevent serious complications such as thrombus and limb amputation. The purpose of this review is to describe the clinical features of heparin-induced thrombocytopenia in children and to summarize the data available for its management. This paper summarizes data and relates the use of direct thrombin inhibitors with clinical outcomes. A literature search was conducted with Ovid, using the key terms argatroban, bivalirudin, hirulog, danaparoid, lepirudin, direct thrombin inhibitor, heparin-induced thrombocytopenia, thrombosis, warfarin, and fondaparinux. Articles were excluded if they were classified as editorials, review articles, or conference abstracts or if they involved patients 18 years of age or older or described disease states not related to thrombosis. Nineteen articles containing 33 case reports were identified and evaluated for this review. Of the 33 cases, 14, 10, 4, and 2 cases described the use of lepirudin, danaparoid, argatroban, and bivalirudin, respectively. Two cases did not report the type of anticoagulant used, and 1 case used aspirin. The most commonly reported complication was bleeding.
Abstract sourced from PubMed (NCBI) for the cited record. See the original publication for the authoritative version.
Resumen
Review of 33 pediatric HIT case reports across 19 articles; lepirudin used in 14 cases, danaparoid in 10, argatroban in 4 and bivalirudin in 2, all leech-derived DTIs feature prominently.
Por qué esto importa para la hirudoterapia
Esta revisión examinó 33 informes de casos pediátricos de trombocitopenia inducida por heparina (TIH) en 19 artículos, resumiendo las características clínicas y los desenlaces del manejo con anticoagulantes alternativos tras la interrupción de la heparina. Cabe destacar que la lepirudina, el agente notificado con mayor frecuencia (14 de 33 casos), es hirudina recombinante, el potente inhibidor directo de la trombina derivado originalmente de la saliva de la sanguijuela medicinal (Hirudo medicinalis), lo que confiere a esta revisión una relevancia directa con la hirudoterapia y las aplicaciones terapéuticas del secretoma de la sanguijuela. Los datos de casos compilados aportan información del mundo real sobre cómo funciona un anticoagulante derivado de la sanguijuela en un contexto clínico serio y especializado. Sin embargo, dado que se trata de una síntesis de informes de casos y no de ensayos controlados, no puede establecer eficacia comparativa ni perfiles de seguridad definitivos, y la complicación más frecuentemente notificada con todos los agentes fue el sangrado.
Citación
Heparin-induced thrombocytopenia in the pediatric population: a review of current literature.
Vakil NH et al. · The journal of pediatric pharmacology and therapeutics, 2012
Contexto clínico relacionado
Explore cómo esta investigación se conecta con la práctica clínica
Añadido a la biblioteca ASH: May 27, 2026 · Última actualización del sitio: 18 de junio de 2026